tingenone has been researched along with Leukemia, Myeloid, Acute in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bezerra, DP; Bomfim, LM; Costa, EV; da Silva, FMA; Dias, RB; Koolen, HHF; Neves, SP; Rocha, CAG; Rocha, WC; Rodrigues, ACBDC; Soares, MBP; Valverde, LF | 1 |
1 other study(ies) available for tingenone and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Tingenone and 22-hydroxytingenone target oxidative stress through downregulation of thioredoxin, leading to DNA double-strand break and JNK/p38-mediated apoptosis in acute myeloid leukemia HL-60 cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Cell Line; Cell Line, Tumor; DNA Breaks, Double-Stranded; Down-Regulation; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Salacia; Thioredoxins; Triterpenes | 2021 |